Medpace Holdings, Inc. (NASDAQ:MEDP) Position Lessened by Bridge City Capital LLC

Bridge City Capital LLC decreased its stake in Medpace Holdings, Inc. (NASDAQ:MEDPGet Rating) by 0.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,276 shares of the company’s stock after selling 104 shares during the period. Medpace accounts for 1.5% of Bridge City Capital LLC’s portfolio, making the stock its 16th largest position. Bridge City Capital LLC owned approximately 0.06% of Medpace worth $3,317,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. BlackRock Inc. lifted its holdings in shares of Medpace by 0.9% in the 1st quarter. BlackRock Inc. now owns 3,792,694 shares of the company’s stock worth $620,448,000 after purchasing an additional 35,121 shares during the last quarter. Wasatch Advisors Inc. lifted its holdings in shares of Medpace by 12.1% in the 1st quarter. Wasatch Advisors Inc. now owns 2,728,392 shares of the company’s stock worth $446,338,000 after purchasing an additional 294,103 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Medpace by 6.2% in the 4th quarter. Invesco Ltd. now owns 985,930 shares of the company’s stock worth $214,578,000 after purchasing an additional 57,837 shares during the last quarter. State Street Corp raised its stake in Medpace by 2.5% during the 1st quarter. State Street Corp now owns 899,855 shares of the company’s stock valued at $147,207,000 after acquiring an additional 21,868 shares in the last quarter. Finally, Echo Street Capital Management LLC raised its stake in Medpace by 18.4% during the 1st quarter. Echo Street Capital Management LLC now owns 695,336 shares of the company’s stock valued at $113,750,000 after acquiring an additional 108,133 shares in the last quarter. Institutional investors own 83.97% of the company’s stock.

Medpace Stock Performance

MEDP opened at $152.90 on Wednesday. Medpace Holdings, Inc. has a one year low of $126.94 and a one year high of $231.00. The stock’s fifty day moving average is $161.34 and its 200-day moving average is $152.64. The company has a market capitalization of $4.74 billion, a PE ratio of 26.55 and a beta of 1.47.

Medpace (NASDAQ:MEDPGet Rating) last posted its quarterly earnings data on Monday, July 25th. The company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.12. Medpace had a return on equity of 30.56% and a net margin of 16.27%. The company had revenue of $351.21 million for the quarter, compared to the consensus estimate of $344.01 million. During the same quarter in the previous year, the business earned $1.06 EPS. The company’s quarterly revenue was up 26.2% compared to the same quarter last year. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 6.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Thursday, September 8th. Guggenheim assumed coverage on Medpace in a research note on Monday, May 23rd. They set a “neutral” rating on the stock. Finally, UBS Group assumed coverage on Medpace in a research note on Wednesday, September 7th. They set a “sell” rating and a $142.00 target price on the stock.

Insider Transactions at Medpace

In other news, CEO August J. Troendle acquired 56,557 shares of the company’s stock in a transaction dated Thursday, September 8th. The shares were bought at an average price of $157.65 per share, with a total value of $8,916,211.05. Following the purchase, the chief executive officer now owns 5,774,100 shares of the company’s stock, valued at $910,286,865. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO August J. Troendle bought 8,330 shares of the firm’s stock in a transaction that occurred on Monday, July 18th. The shares were acquired at an average cost of $145.00 per share, for a total transaction of $1,207,850.00. Following the acquisition, the chief executive officer now directly owns 5,513,639 shares of the company’s stock, valued at approximately $799,477,655. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO August J. Troendle bought 56,557 shares of the firm’s stock in a transaction that occurred on Thursday, September 8th. The stock was bought at an average price of $157.65 per share, for a total transaction of $8,916,211.05. Following the completion of the acquisition, the chief executive officer now directly owns 5,774,100 shares in the company, valued at $910,286,865. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 87,177 shares of company stock valued at $13,346,972. Corporate insiders own 20.60% of the company’s stock.

Medpace Company Profile

(Get Rating)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Featured Stories

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDPGet Rating).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.